RU2012116880A - Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов - Google Patents

Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов Download PDF

Info

Publication number
RU2012116880A
RU2012116880A RU2012116880/15A RU2012116880A RU2012116880A RU 2012116880 A RU2012116880 A RU 2012116880A RU 2012116880/15 A RU2012116880/15 A RU 2012116880/15A RU 2012116880 A RU2012116880 A RU 2012116880A RU 2012116880 A RU2012116880 A RU 2012116880A
Authority
RU
Russia
Prior art keywords
alpha
ethylene oxide
nanoparticle
hydroxyphosphonate
nanoparticles
Prior art date
Application number
RU2012116880/15A
Other languages
English (en)
Inventor
Брайан К. БЭЙЛС
Брюс Алан ХЭЙ
Бинил Айтти Айпе КАНДАПАЛЛИЛ
Original Assignee
Дженерал Электрик Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженерал Электрик Компани filed Critical Дженерал Электрик Компани
Publication of RU2012116880A publication Critical patent/RU2012116880A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

1. Композиция, содержащая:нерастворимую в воде наночастицу, к которой присоединена по меньшей мере одна альфа-гидроксифосфонатная группировка, имеющая формулу:где S представляет собой спейсер, L представляет собой связь между S и R, R представляет собой полимерную гидрофильную группировку, m и p равны 1-5, и n и o равны 0-5.2. Композиция по п.1, где R представляет собой полимерную гидрофильную группировку на основе этиленоксидных единиц.3. Композиция по п.1 или 2, где полимерные гидрофильные группировки основаны на этиленоксиде, и где поли(этиленоксид) имеет молекулярную массу, равную или меньше 5000 Да.4. Композиция по п.1, где наночастица представляет собой суперпарамагнитную наночастицу на основе оксида железа.5. Композиция по п.1, дополнительно содержащая фармацевтически приемлемый носитель или эксципиент.6. Композиция по п.5 для применения в качестве контрастного агента МРВ (магнитно-резонансная визуализация), подходящего для инъецирования субъекту-человеку.7. Способ использования нерастворимых в воде наночастиц, к которым присоединены альфа-гидроксифосфонатные группировки, в диагностической визуализации, включающийа) введение указанных наночастиц субъекту; иб) подвергание указанного субъекта диагностической визуализации, при которой указанные наночастицы действуют в качестве контрастного агента.8. Способ по п.7, где альфа-гидроксифосфонатные группировки имеют формулу:где S представляет собой спейсер, L представляет собой связь между S и R, R представляет собой полимерную гидрофильную группировку, m и p равны 1-5, и n и o равны 0-5.9. Способ по п.8, где R представляет собой полимерную гидрофильную группировку на основе этиленок�

Claims (15)

1. Композиция, содержащая:
нерастворимую в воде наночастицу, к которой присоединена по меньшей мере одна альфа-гидроксифосфонатная группировка, имеющая формулу:
Figure 00000001
где S представляет собой спейсер, L представляет собой связь между S и R, R представляет собой полимерную гидрофильную группировку, m и p равны 1-5, и n и o равны 0-5.
2. Композиция по п.1, где R представляет собой полимерную гидрофильную группировку на основе этиленоксидных единиц.
3. Композиция по п.1 или 2, где полимерные гидрофильные группировки основаны на этиленоксиде, и где поли(этиленоксид) имеет молекулярную массу, равную или меньше 5000 Да.
4. Композиция по п.1, где наночастица представляет собой суперпарамагнитную наночастицу на основе оксида железа.
5. Композиция по п.1, дополнительно содержащая фармацевтически приемлемый носитель или эксципиент.
6. Композиция по п.5 для применения в качестве контрастного агента МРВ (магнитно-резонансная визуализация), подходящего для инъецирования субъекту-человеку.
7. Способ использования нерастворимых в воде наночастиц, к которым присоединены альфа-гидроксифосфонатные группировки, в диагностической визуализации, включающий
а) введение указанных наночастиц субъекту; и
б) подвергание указанного субъекта диагностической визуализации, при которой указанные наночастицы действуют в качестве контрастного агента.
8. Способ по п.7, где альфа-гидроксифосфонатные группировки имеют формулу:
Figure 00000002
где S представляет собой спейсер, L представляет собой связь между S и R, R представляет собой полимерную гидрофильную группировку, m и p равны 1-5, и n и o равны 0-5.
9. Способ по п.8, где R представляет собой полимерную гидрофильную группировку на основе этиленоксидных единиц.
10. Способ по п.9, где полимерные гидрофильные группировки основаны на этиленоксиде, и где поли(этиленоксид) имеет молекулярную массу, равную или меньше 5000 Да.
11. Способ по любому из пп.7-10, где наночастица представляет собой суперпарамагнитную наночастицу на основе оксида железа.
12. Способ изготовления нерастворимых в воде наночастиц, к которым присоединены альфа-гидроксифосфонатные группировки, включающий:
а) получение суспензии наночастицы в суспензионном агенте; и
б) приведение указанной суспензии в контакт с указанными альфа-гидроксифосфонатными группировками.
13. Способ по п.12, где альфа-гидроксифосфонатные группировки имеют формулу:
Figure 00000003
где S представляет собой спейсер, L представляет собой связь между S и R, R представляет собой полимерную гидрофильную группировку, m и p равны 1-5, и n и o равны 0-5.
14. Способ по п.13, где R представляет собой гидрофильную группировку на основе этиленоксидных единиц.
15. Способ по п.14, где полимерные гидрофильные группировки основаны на этиленоксиде, и где поли(этиленоксид) имеет молекулярную массу, равную или меньше 5000 Да.
RU2012116880/15A 2009-10-30 2010-10-29 Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов RU2012116880A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/609,799 2009-10-30
US12/609,799 US9205155B2 (en) 2009-10-30 2009-10-30 Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
PCT/EP2010/066429 WO2011051422A2 (en) 2009-10-30 2010-10-29 Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents

Publications (1)

Publication Number Publication Date
RU2012116880A true RU2012116880A (ru) 2013-12-10

Family

ID=43480950

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012116880/15A RU2012116880A (ru) 2009-10-30 2010-10-29 Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов

Country Status (13)

Country Link
US (2) US9205155B2 (ru)
EP (1) EP2493512B1 (ru)
JP (1) JP5997609B2 (ru)
KR (1) KR20120101362A (ru)
CN (1) CN102639153B (ru)
AU (1) AU2010311437A1 (ru)
BR (1) BR112012010113A2 (ru)
CA (1) CA2777871A1 (ru)
ES (1) ES2720152T3 (ru)
IN (1) IN2012DN02804A (ru)
MX (1) MX2012005022A (ru)
RU (1) RU2012116880A (ru)
WO (1) WO2011051422A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767430C2 (ru) * 2017-06-28 2022-03-17 Рикен Наночастица, содержащее ее контрастное вещество для магнитно-резонансной томографии и лигандное соединение

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986836B2 (en) * 2009-03-19 2015-03-24 Ohio University Microspheres and their methods of preparation
US8920681B2 (en) * 2009-12-30 2014-12-30 Korea University Research And Business Foundation Electrically conductive polymers with enhanced conductivity
BR112013013929A2 (pt) * 2010-12-15 2016-09-13 Gen Electric composição de nanopartícula, e, processos para fabricar uma composição de nanopartícula e de formação de imagem de diagnóstico
US8889103B2 (en) 2010-12-15 2014-11-18 General Electric Company Diagnostic agent composition and associated methods thereof
US8895068B2 (en) 2010-12-15 2014-11-25 General Electric Company Nanoparticle composition and associated methods thereof
US9474810B2 (en) * 2012-03-02 2016-10-25 General Electric Company Superparamagnetic nanoparticles with PEG substituted α-hydroxy phosphonate shells
US9251937B2 (en) 2012-06-29 2016-02-02 General Electric Company Heat stable nanoparticle preparations and associated methods thereof
US20190001001A1 (en) * 2017-07-03 2019-01-03 General Electric Company Drug design for application-dependent payload, controlled pharmacokinetic distribution, and renal clearance
US11577977B2 (en) * 2017-09-26 2023-02-14 The Board Of Trustees Of The University Of Arkansas Composite zero valent iron nanoparticles and applications thereof
CN110734460B (zh) * 2019-10-22 2022-03-29 华南师范大学 一类磺酸-膦酸配体的制备及其用途
CN118748269B (zh) * 2024-08-05 2025-10-31 瑞固(衢州)新材料科技有限公司 一种硫化物固态电解质及其制备方法与电池

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5651493A (en) 1979-10-02 1981-05-09 Yoshitomi Pharmaceut Ind Ltd Diphosphoglycerol and its preparation
JPS6043217A (ja) 1983-08-19 1985-03-07 Toshiba Corp 磁気記録媒体
DE3343586A1 (de) 1983-11-29 1985-06-05 Herbert Dr. 1000 Berlin Pilgrimm Verfahren zur entkeimung eines mediums und vorrichtung zur durchfuehrung
DE3440190A1 (de) 1984-11-01 1986-05-15 Michel-Kim, Herwig, 1000 Berlin Verfahren und vorrichtung zur erzeugung von stickstoffduenger und stickstoffangereicherter biomasse aus luft
DE3443810A1 (de) 1984-11-28 1986-05-28 Herbert Dr. 1000 Berlin Pilgrimm Verfahren zur entkeimung eines mediums
DE3624626A1 (de) 1986-07-18 1988-01-28 Pilgrimm Herbert Verfahren zur abtrennung von stoffen aus einem stoffgemisch unter verwendung von magnetischen fluessigkeiten
DE3709852A1 (de) 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Stabile magnetische fluessigkeitszusammensetzungen und verfahren zu ihrer herstellung und ihre verwendung
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
DE4309333A1 (de) 1993-03-17 1994-09-22 Silica Gel Gmbh Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben
ATE156706T1 (de) * 1993-03-17 1997-08-15 Silica Gel Gmbh Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
EP0772776B1 (de) * 1994-07-27 2000-03-22 Herbert Dr. Pilgrimm Superparamagnetische teilchen, verfahren zur herstellung und deren verwendung
DE19612001A1 (de) * 1996-03-18 1997-09-25 Silica Gel Gmbh Adsorptions Te Superparamagnetische Teilchen mit vergrößerter R¶1¶-Relaxivität, Verfahren zur Herstellung und deren Verwendung
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
DE10016559A1 (de) 2000-04-03 2001-10-18 Eucro Europe Contract Res Gmbh System für den Transport von Aktivstoffen in einem biologischen System
ATE472511T1 (de) 2001-08-16 2010-07-15 Essilor Int Verfahren zur herstellung stabiler dispersionen metallischer nanopartikel, stabile dispersion hergestellt auf basis dieses verfahrens und beschichtungszusammensetzungen enthaltend diese dispersionen
DE10222481A1 (de) * 2002-05-22 2003-12-04 Eucro Europe Contract Res Gmbh Kontrastmittel für die Verwendung in bildgebenden Verfahren
US6797380B2 (en) 2002-07-31 2004-09-28 General Electric Company Nanoparticle having an inorganic core
JP2006502572A (ja) * 2002-10-09 2006-01-19 フェロファーマ ゲーエムベーハー フォルシュングスラボア 安定化超常磁性粒子
US7560160B2 (en) * 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
FR2848850B1 (fr) * 2002-12-20 2005-06-24 Guerbet Sa Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates.
US20040161435A1 (en) 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
DE10323816A1 (de) * 2003-05-23 2004-12-09 Basf Ag Verfahren zur Herstellung von Mischoxiden mit mittleren Durchmessern kleiner als 10 Nanometer
US20060018835A1 (en) * 2004-04-02 2006-01-26 General Electric Company Nanoparticles with inorganic core and methods of using them
CN100334166C (zh) 2005-01-26 2007-08-29 上海大学 一种纳米碳酸钙的改性方法
US8084275B2 (en) * 2005-02-08 2011-12-27 Fujifilm Corporation Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
KR100746312B1 (ko) * 2005-03-14 2007-08-03 한국화학연구원 수용성 산화철 나노 입자 및 이의 제조방법
EP1888311A4 (en) 2005-05-12 2011-06-22 Georgia Tech Res Inst COATED METAL OXIDE NANOTEHICLES AND MANUFACTURING METHOD THEREFOR
US7767736B2 (en) 2005-12-05 2010-08-03 3M Innovative Properties Company Flame retardant polymer composition
DE102005059751A1 (de) 2005-12-09 2007-06-14 Ferropharm Gmbh Forschungslabor Wässrige Dispersion von superparamagnetischen Eindomänenteilchen, deren Herstellung und Verwendung zur Diagnose und Therapie
ITFI20060006A1 (it) 2006-01-04 2007-07-05 Colorobbia Italiana Spa Nanoparticelle funzionalizzate, loro produzione ed uso
DE102006007888A1 (de) 2006-02-21 2007-08-23 Degussa Gmbh Aluminiumoxid enthaltende Dispersion, Zubereitung enthaltend diese Dispersion und ein Melaminharz und mittels dieser Zubereitung hergestelles gehärtetes Produkt
WO2007133801A2 (en) 2006-05-15 2007-11-22 Dmitri B Kirpotin Magnetic microparticles comprising organic substances
FR2904784B1 (fr) * 2006-08-10 2010-09-03 Surfactis Technologies Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations
US20080299046A1 (en) 2006-10-16 2008-12-04 The Trustees Of Columbia University In The City Of New York Methods for controlling surface functionality of metal oxide nanoparticles, metal oxide nanoparticles having controlled functionality, and uses thereof
US8258190B2 (en) 2007-04-30 2012-09-04 Intezyne Technologies, Inc. Encapsulated contrast agents
US9072789B2 (en) 2007-07-20 2015-07-07 The Trustees Of Princeton University Nano-particle surface modification
SG150405A1 (en) 2007-08-29 2009-03-30 Agency Science Tech & Res Method of coating a particle
FR2921838A1 (fr) * 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
KR20090038337A (ko) 2007-10-15 2009-04-20 재단법인서울대학교산학협력재단 무기계 나노입자를 수계 매질에 분산시키는 생체적합성분산 안정화제
CN101951890A (zh) 2007-12-13 2011-01-19 阿杜罗生物技术公司 配体缀合的热疗感受器及其制备方法
US20090226376A1 (en) * 2008-03-05 2009-09-10 General Electric Company Novel Mixed Ligand Core/Shell Iron Oxide Nanoparticles for Inflammation Imaging
US8173198B2 (en) 2008-07-23 2012-05-08 Life Technologies Corporation Deposition of metal oxides onto surfaces as an immobilization vehicle for carboxylated or phophated particles or polymers
US20100166664A1 (en) 2008-12-29 2010-07-01 General Electric Company Nanoparticle contrast agents for diagnostic imaging

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767430C2 (ru) * 2017-06-28 2022-03-17 Рикен Наночастица, содержащее ее контрастное вещество для магнитно-резонансной томографии и лигандное соединение
US11389550B2 (en) 2017-06-28 2022-07-19 Riken Nanoparticle, contrast agent for magnetic resonance imaging containing same, and ligand compound

Also Published As

Publication number Publication date
CN102639153B (zh) 2017-02-22
US20160038617A1 (en) 2016-02-11
EP2493512B1 (en) 2019-01-23
KR20120101362A (ko) 2012-09-13
IN2012DN02804A (ru) 2015-07-24
AU2010311437A1 (en) 2012-04-12
JP5997609B2 (ja) 2016-09-28
JP2013509381A (ja) 2013-03-14
CN102639153A (zh) 2012-08-15
CA2777871A1 (en) 2011-05-05
US9827335B2 (en) 2017-11-28
EP2493512A2 (en) 2012-09-05
BR112012010113A2 (pt) 2019-09-24
ES2720152T3 (es) 2019-07-18
WO2011051422A2 (en) 2011-05-05
US20110104072A1 (en) 2011-05-05
US9205155B2 (en) 2015-12-08
MX2012005022A (es) 2012-06-08
WO2011051422A3 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
RU2012116880A (ru) Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов
Kim et al. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle
Park et al. Multi-modal transfection agent based on monodisperse magnetic nanoparticles for stem cell gene delivery and tracking
Lin et al. Carboxymethyl chitosan-assisted MnOx nanoparticles: Synthesis, characterization, detection and cartilage repair in early osteoarthritis
Hao et al. Multifunctional nanosheets based on folic acid modified manganese oxide for tumor-targeting theranostic application
Wang et al. Antifouling manganese oxide nanoparticles: synthesis, characterization, and applications for enhanced MR imaging of tumors
ES2787502T3 (es) Polímero biocompatible y nanopartícula magnética con biocompatibilidad
Yin et al. Biocompatible folate-modified Gd 3+/Yb 3+-doped ZnO nanoparticles for dualmodal MRI/CT imaging
JP2013509381A5 (ru)
CN113546087B (zh) 一种纤连蛋白包覆的单宁酸/铁配合物的载药纳米材料及其制备和应用
ES2333087A1 (es) Micelas polimericas dendriticas sensibles al ph.
ES2718424T3 (es) Un procedimiento para preparar nanopartículas poliméricas monocatenarias dispersables en agua
Meng et al. Matrix metalloproteinase-initiated aggregation of melanin nanoparticles as highly efficient contrast agent for enhanced tumor accumulation and dual-modal imaging
Li et al. A pH-responsive magnetic resonance tuning probe for precise imaging of bacterial infection in vivo
Wei et al. Excitation-selectable nanoprobe for tumor fluorescence imaging and near-infrared thermal therapy
Gharehaghaji et al. PEGylated Magnetite/Hydroxyapatite: A Green Nanocomposite for T2‐Weighted MRI and Curcumin Carrying
Wu et al. Multifunctional nanostructures for tumor-targeted molecular imaging and photodynamic therapy
Jiang et al. Carbon quantum dots carrying antibiotics for treating dental implant bacterial infections following photothermal therapy
CN105327367B (zh) 一种成像剂、制备方法和用途
Zhang et al. Functionalized magnetic nanochains with enhanced MR imaging: a novel nanosystem for targeting and inhibition of early glioma
Wang et al. Insights into Non‐Metallic Magnetic Resonance Imaging Contrast Agents: Advances and Perspectives
CN106178004A (zh) 一种磁性纳米诊疗剂及其制备方法和应用
CN113616815A (zh) pH响应的T1/T2切换型MRI造影剂及其制备方法与应用
CN103432585A (zh) 叶酸受体α亚型高效介导的靶向标记系统
CN106310297B (zh) 多功能高分子前药纳米递药系统及制备方法和用途

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20160627